Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 19, 2026.

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

Véronique Gelsi-Boyer, Mandy Brecqueville, Raynier Devillier and 3 more

Journal of Hematology & Oncology · 2012 · Review

doi:10.1186/1756-8722-5-12

Abstract

The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 19, 2026. Paragraph numbers are ours, so an answer can point at one.

Mutations in the ASXL1 (additional sex combs like 1) gene were first reported in 2009 in myelodysplastic syndromes. ASXL1 maps to chromosome region 20q11, close to the DNMT3B gene, and belongs to a family of three paralogs. ASXL1 comprises 12 exons and is expressed in most hematopoietic cell types.

Function of the ASXL1 protein

ASXL1 codes for a nuclear protein of 1084 residues characterized by an N-terminal helix-turn-helix domain, HARE-HTH, and an unusual C-terminal plant homeodomain (PHD), which may bind methylated lysines (Figure 1). The central part of ASXL1 contains an ASXH globular domain that may interact with a polycomb-associated deubiquitinase (DUB). ASXL1 regulates epigenetic marks and transcription through interaction with polycomb complex proteins and various transcription activators and repressors. In Drosophila, ASX forms a complex with the ubiquitin carboxy-terminal hydrolase calypso to constitute the recently identified polycomb repressive deubiquitinase (PR-DUB) complex. Human wild-type ASXL1 associates with the calypso ortholog BAP1. The calypso/BAP1 DUB deubiquitylates K119ub on histone H2A, leading to gene repression. However, the role of ASXL1 in leukemogenesis does not seem to be mediated by the DUB complex. Recent data have shown that ASXL1 interacts with components of the polycomb complex PRC2, namely EZH2 and SUZ12, two proteins involved in the deposition of H3K27me3 histone repressive marks. These two PRC2 components are also mutated in myeloid malignant diseases. Inhibition of ASXL1 function leads to loss of H3K27me3 histone marks. ASXL1 role could be to recruit the PRC2 complex to known leukemogenic loci such as HOXA genes. ASXL1 also associates with HP1α/CBX5, a component of the heterochromatin repressive complex. HP1α binds to histone H3. JAK2 phosphorylates histone H3 and excludes HP1α from chromatin. Thus, a potential functional link may exist between ASXL1 and JAK2 mutations but this remains to be demonstrated.

The functions of the other ASXL proteins are poorly defined. ASXL2 has been shown to regulate heart and bone development, as well as adipogenesis. Mouse ASXL2 has been identified as a regulator of bone mineral density and osteoclastogenesis and whereas ASXL1 represses, ASXL2 increases the expression of adipogenic genes. ASXL3 expression and functions remain to be determined.

ASXL1 and concomitant mutations in myeloid malignancies

The vast majority of the ASXL1 mutations found in myeloid malignancies affect the twelfth exon of the gene although rare mutations in other exons have been detected. ASXL1 mutations are frameshift and nonsense mutations that are supposed to result in C-terminal truncation of the protein upstream of the PHD finger (Figure 1). The functional relevance of some reported missense mutations is not clear. The most frequent mutation, which accounts for more than 50% of all ASXL1 mutations, is a duplication of a guanine nucleotide (c.1934dupG); it leads to a frameshift (p.Gly646TrpfsX12). One study has described this mutation as a PCR artefact, but because it is not found in germ-line DNAs, control DNAs or other studied types of cancers such as breast cancer, it is now generally considered to be a bona fide mutation.

ASXL1 mutations are usually heterozygous, suggesting that haplo-insufficiency is the key pathological factor; however, the truncated ASXL1 protein could also have a dominant negative role in titrating out an interacting protein. Actually, recent data have demonstrated a loss of ASXL1 protein in leukemia samples with ASXL1 mutation, indicating that these mutations are loss-of-function disease alleles.

ASXL1 is mutated in all types of malignant myeloid diseases, including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). According to the series studied, ASXL1 mutation frequency varies from a few percent to more than 50% of cases (Table 1). ASXL1 mutations are most frequent in CMML (~ 45%). In MPNs, they are frequent in primary myelofibrosis (PMF)(34.5%) and rare in polycythemia vera (PV) or essential thrombocythemia (ET). In AML, they are found in secondary (30%) rather than in de novo cases (6.5%), and in AML with normal karyotype ASXL1 mutations are mutually exclusive with NPM1 mutations. ASXL1 is the second most frequently mutated gene in MDSs after TET2. In MDSs, ASXL1 mutations are more frequent in refractory anemia with excess of blasts (RAEB) than in the other forms such as refractory anemia with ring sideroblasts (RARS). ASXL1 mutations are further detected in rare cases of juvenile myelomonocytic leukemia (JMML) and in RARS-T.

With the exception of NPM1 and FLT3, it seems that ASXL1 mutations coincide with mutations in many known genes including EZH2, IDH1/2, RUNX1 and TET2. Although ASXL1 functions are related to the PRC2 complex, which includes EZH2, ASXL1 and EZH2 mutations are not mutually exclusive. ASXL1 mutations can also cooperate with mutations in genes encoding signaling (CBL, JAK2, NF1, RAS) and splicing proteins (SF3B1, SRSF2, U2AF35). For example, in MDSs, ASXL1 mutations are more frequent in U2AF35-mutated patients than in U2AF35 wild-type patients. In MPNs, ASXL1 mutations are found with the same frequency in JAK2V617F and JAK2 wild-type cases. In MDSs, ASXL1 mutations are often associated with RUNX1 mutations, and, in AMLs, with RUNX1 and CEBPA..

Other alterations in ASXL1, ASXL2 and ASXL3

Few deletions of the gene have been reported and ASXL1 is generally not included in the more telomeric 20q13 deletion that is often observed in myeloid diseases. The ASXL1 gene can be translocated and fused to the PAX5 gene in acute lymphoblastoid leukemia and altered by germ-line mutations in the Bohring-Opitz syndrome; this severe syndrome leads to death at an early age preventing to know whether susceptibility to hematopoietic diseases might result from ASXL1 germ-line mutations. In recent genome sequencing studies rare mutations in ASXL1 and ASXL3 have also been found in chronic lymphocytic leukemia but not in T-cell acute leukemia. Mutations in ASXL2 and ASXL3 have not been found in myeloid diseases so far, but ASXL2-MYST3 and EPC1-ASXL2 fusions have been identified in myelodysplastic syndrome and T-cell acute leukemia, respectively. Both MYST3 and EPC1 are epigenetic regulators and these fusion proteins probably disrupt epigenetic protein complexes.

Animal models of ASXL1 loss

In a first model of Asxl1 gene knock-out in the mouse ASXL1 loss mildly perturbed myelopoiesis but did not trigger an actual hematological malignancy. However, the effect of the absence of ASXL1 protein may have been masked by partially penetrant perinatal lethality. In another, more recent model of conditional Asxl1 gene knock-out, the animals developed a strong hematopoietic phenotype consistent with an MDS with myeloproliferative features. In cooperation with NRAS oncogenic mutation the absence of ASXL1 triggered an MDS/MPN. These observations were confirmed by experiments in hematopoietic cells using shRNA directed against ASXL1, which were highly coherent with the expected role of ASXL1 in leukemogenesis.

ASXL1 mutations in disease evolution

Like TET2 mutations, ASXL1 mutations are found in chronic and acute stages of myeloid malignancies. In a study of MPNs, with the exception of a single patient who acquired both ASXL1 and TET2 mutations, all patients with ASXL1 mutation at leukemic transformation already had ASXL1 mutation at the chronic stage. In a series of secondary AML with multilineage dysplasia we found that in cases resulting from a transformation of a known MDS the same ASXL1 mutation was present at both the chronic and acute stages (Devillier et al., submitted). These observations suggest that ASXL1 mutations may constitute early hits in leukemogenesis and precede other alterations such as JAK2 and TET2 mutations. However, there is also evidence to suggest that the opposite is true in some cases. In MPNs, for example, the proportion of ASXL1 mutations is higher in post-PV myelofibrosis (MF) and post-ET MF than in PV and ET. This suggests that the ASXL1 mutation may follow a JAK2 mutation and could therefore help predict the risk of evolution from PV and ET to MF. As such, ASXL1 mutations may play a crucial role in the pathogenesis of PMF, as well as in the molecular progression from the chronic phase of a previous PV or ET to MF. Finally, in MDSs and CMML, ASXL1 mutations seem to be present in chronic phases and precede transformation and in rare cases, ASXL1 mutations can be lost or acquired during relapse of de novo AML.

ASXL1 mutations in disease outcome

A number of studies have linked ASXL1 mutations to the outcome of malignant myeloid diseases. In a study of MPNs based on the DIPSS-plus score (Dynamic International Prognostic Scoring System for primary myelofibrosis), ASXL1 mutation tended to be associated with an aggressive disease and a poor overall survival. In a large study of PMF patients ASXL1 mutations were associated with shorter overall survival. In CMML, the presence of an ASXL1 mutation could help predict transformation to AML. In MDSs, ASXL1 mutations are associated with a reduced time to progression in AML and constitute an independent prognostic marker. Finally, a study of 18 genes in a large cohort of MDSs showed that mutations in 5 genes had prognostic impact: TP53, EZH2, ETV6, RUNX1 and ASXL1. Coupled with the standardized international prognostic scoring system (IPSS), mutations in these five genes could help refine the prognosis evaluation of MDSs.

By contrast, a study of a large cohort of 605 AML cases without cytogenetic prognostic markers other than 11q23 abnormalities, reported that ASXL1 mutations were not associated with outcome. However, they were associated with shorter overall survival in patients with intermediate-risk AML. A recent study of 476 cases with intermediate-risk de novo AML showed that ASXL1 mutations have a major impact on outcome. According to the current European LeukemiaNet (ELN) guidelines for the diagnosis and management of AML, AMLs with normal karyotype are classified into two genetic categories based on their NPM1, FLT3-ITD and CEBPA mutation status: the ELN Favorable category is defined as mutated CEBPA and/or mutated NPM1 without FLT3-IT; all remaining cases (ie, those with wild-type CEBPA, and wild-type NPM1 with or without FLT3-ITD or mutated NPM1 with FLT3-ITD) form the ELN Intermediate-I category. ASXL1 mutations have been associated with inferior survival among ELN Favorable, but not among ELN Intermediate-I patients. Taken together, these data show that ASXL1 mutations have prognostic value in certain subgroups of AML patients.

Conclusion

In almost all studies, and whatever the type of myeloid malignancy, ASXL1 mutations are associated with adverse features including, but not limited to myelodysplasia, myelofibrosis or progression to AML. Systematic detection of ASXL1 mutations could thus help in the assessment of disease and should perhaps be implemented in routine practice, whether associated with already systematically-surveyed mutations (CEBPA, JAK2, FLT3, NPM1) or in upcoming systematic genome analyses.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors have contributed ideas, discussions, and have participated in the writing of the manuscript. All authors read and approved the final manuscript

References 53

  1. 1.

    Gelsi-Boyer V Trouplin V Adelaide J Bonansea J Cervera N Carbuccia N Lagarde A Prebet T Nezri M Sainty D Olschwang S Xerri L Chaffanet M Mozziconacci MJ Vey N Birnbaum D Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemiaBr J Haematol2009 145788800

    Not in our library10.1111/j.1365-2141.2009.07697.x

  2. 2.

    Aravind L Iyer LM The HARE-HTH and associated domains: Novel modules in the coordination of epigenetic DNA and protein modificationsCell Cycle2012 111119131

    Not in our library10.4161/cc.11.1.18475

  3. 3.

    Scheuermann JC de Ayala Alonso AG Oktaba K Ly-Hartig N McGinty RK Fraterman S Wilm M Muir TW Müller J Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUBNature2010 465243247

    Not in our library10.1038/nature08966

  4. 4.

    Cho YS Kim EJ Park UH Sin HS Um SJ Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptorJ Biol Chem2006 2811758817598

    Not in our library10.1074/jbc.m512616200

  5. 5.

    Boultwood J Perry J Pellagatti A Fernandez-Mercado M Fernandez-Santamaria C Calasanz MJ Larrayoz MJ Garcia-Delgado M Giagounidis A Malcovati L Della Porta MG Jädersten M Killick S Hellström-Lindberg E Cazzola M Wainscoat JS Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemiaLeukemia2010 2410621065

    Not in our library10.1038/leu.2010.20

  6. 6.

    Beisel C Paro R Silencing chromatin: comparing modes and mechanismsNat Rev Genet2011 12123135

    Not in our library10.1038/nrg2932

  7. 7.

    Abdel-Wahab O Adli M Saunders L Gao J Shih AH Pandey S Jaffe J Zhao X Perna F Carroll M Melnick A Nimer SD Aifantis I Bernstein B Levine RL ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. Abstract 405, ASH December 2011Session: 603 Oncogenes and Tumor Suppressors: From Genomic-based Discovery to Functional Validation

    Not in our library

  8. 8.

    Ernst T Chase AJ Score J Hidalgo-Curtis CE Bryant C Jones AV Waghorn K Zoi K Ross FM Reiter A Hochhaus A Drexler HG Duncombe A Cervantes F Oscier D Boultwood J Grand FH Cross NC Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disordersNat Genet2010 42722726

    Not in our library10.1038/ng.621

  9. 9.

    Nikoloski G Langemeijer SM Kuiper RP Knops R Massop M Tönnissen ER van der Heijden A Scheele TN Vandenberghe P de Witte T van der Reijden BA Jansen JH Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromesNat Genet2010 42665667

    Not in our library10.1038/ng.620

  10. 10.

    Brecqueville M Cervera N Adelaide J Rey J Carbucia N Chaffanet M Vey N Murati A Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasmsBlood Cancer Journal2011 133

    Not in our library10.1038/bcj.2011.31

  11. 11.

    Score J Hidalgo-Curtis C Jones AV Winkelmann N Skinner A Ward D Zoi K Ernst T Stegelmann F Döhner K Chase A Cross NC Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasmsBlood2012 11912081213

    Not in our library10.1182/blood-2011-07-367243

  12. 12.

    Lee SW Cho YS Na JM Park UH Kang M Kim EJ Um SJ ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1J Biol Chem2010 2851829

    Not in our library10.1074/jbc.m109.065862

  13. 13.

    Dawson MA Bannister AJ Gottgens B Foster SD Bartke T Green AR Kouzarides T JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatinNature2009 461819822

    Not in our library10.1038/nature08448

  14. 14.
    Functional conservation of Asxl2, a murine homolog for the Drosophila enhancer of trithorax and polycomb group gene Asx. · 2009
    Not checked
  15. 15.

    Farber CR Bennett BJ Orozco L Zou W Lira A Kostem E Kang HM Furlotte N Berberyan A Ghazalpour A Suwanwela J Drake TA Eskin E Wang QT Teitelbaum SL Lusis AJ Mouse genome-wide association and systems genetics identify Asxl2 as a regulator of bone mineral density and osteoclastogenesisPLoS Genet2011 7e1002038

    Not in our library10.1371/journal.pgen.1002038

  16. 16.

    Park UH Yoon SK Park T Kim EJ Um SJ Additional sex comb-like (ASXL) proteins 1 and 2 play opposite roles in adipogenesis via reciprocal regulation of peroxisome proliferator-activated receptor {gamma}J Biol Chem2011 28613541363

    Not in our library10.1074/jbc.m110.177816

  17. 17.

    Katoh M Katoh M Identification and characterization of human CXXC10 gene in silicoInt J Oncol2004 2511931199

    Not in our library

  18. 18.

    Abdel-Wahab O Pardanani A Patel J Wadleigh M Lasho T Heguy A Beran M Gilliland DG Levine RL Tefferi A Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasmsLeukemia2011 2512001202

    Not in our library10.1038/leu.2011.58

  19. 19.

    Abdel-Wahab O Kilpivaara O Patel J Busque L Levine RL The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alterationLeukemia2010 2416561657

    Not in our library10.1038/leu.2010.144

  20. 20.

    Carbuccia N Trouplin V Gelsi-Boyer V Murati A Rocquain J Adélaïde J Olschwang S Xerri L Vey N Chaffanet M Birnbaum D Mozziconacci MJ Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemiasLeukemia2010 24469473

    Not in our library10.1038/leu.2009.218

  21. 21.

    Bejar R Stevenson K Abdel-Wahab O Bejar R Stevenson K Abdel-Wahab O Galili N Nilsson B Garcia-Manero G Kantarjian H Raza A Levine RL Neuberg D Ebert BL Clinical effect of point mutations in myelodysplastic syndromesN Engl J Med2011 36424962506

    Not in our library10.1056/nejmoa1013343

  22. 22.
    Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias · 2010
    No notice
  23. 23.

    Sugimoto Y Muramatsu H Makishima H Prince C Jankowska AM Yoshida N Xu Y Nishio N Hama A Yagasaki H Takahashi Y Kato K Manabe A Kojima S Maciejewski Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutationsBr J Haematol2010 1508387

    Not in our library10.1111/j.1365-2141.2010.08196.x

  24. 24.

    Szpurka H Jankowska AM Makishima H Bodo J Bejanyan N Hsi ED Sekeres MA Maciejewski JP Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutationsLeuk Res2010 34969973

    Not in our library10.1016/j.leukres.2010.02.033

  25. 25.

    Abdel-Wahab O Manshouri T Patel J Harris K Yao J Hedvat C Heguy A Bueso-Ramos C Kantarjian H Levine RL Verstovsek S Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemiasCancer Res2010 70447452

    Not in our library10.1158/0008-5472.can-09-3783

  26. 26.

    Brecqueville M Rey J Bertucci F Coppin E Finetti P Carbuccia N Cervera N Gelsi-Boyer V Arnoulet C Gisserot O Verrot D Slama B Vey N Mozziconacci MJ Birnbaum D Murati A Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12 and TET2 in myeloproliferative neoplasmsGenes Chromosome Cancer2012 in press

    Not in our library10.1002/gcc.21960

  27. 27.

    Boultwood J Perry J Zaman R Fernandez-Santamaria C Littlewood T Kusec R Pellagatti A Wang L Clark RE Wainscoat JS High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progressionLeukemia2010 2411391145

    Not in our library10.1038/leu.2010.65

  28. 28.

    Carbuccia N Murati A Trouplin V Brecqueville M Adélaïde J Rey J Vainchenker W Bernard OA Chaffanet M Vey N Birnbaum D Mozziconacci MJ Mutations of ASXL1 gene in myeloproliferative neoplasmsLeukemia2009 2321832186

    Not in our library10.1038/leu.2009.141

  29. 29.

    Chou WC Huang HH Hou HA Chen CY Tang JL Yao M Tsay W Ko BS Wu SJ Huang SY Hsu SC Chen YC Huang YN Chang YC Lee FY Liu MC Liu CW Tseng MH Huang CF Tien HF Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutationsBlood2011 11640864094

    Not in our library10.1182/blood-2010-05-283291

  30. 30.

    Gelsi-Boyer V Trouplin V Roquain J Adélaïde J Carbuccia N Esterni B Finetti P Murati A Arnoulet C Zerazhi H Fezoui H Tadrist Z Nezri M Chaffanet M Mozziconacci MJ Vey N Birnbaum D ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemiaBr J Haematol2010 151365375

    Not in our library10.1111/j.1365-2141.2010.08381.x

  31. 31.

    Grossmann V Kohlmann A Eder C Haferlach C Kern W Cross NC Haferlach T Schnittger S Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in > 80% of patients with TET2 and EZH2 being of high prognostic relevanceLeukemia2012 25877879

    Not in our library10.1038/leu.2011.10

  32. 32.

    Jankowska AM Makishima H Tiu RV Szpurka H Huang Y Traina F Visconte V Sugimoto Y Prince C O'Keefe C Hsi ED List A Sekeres MA Rao A McDevitt MA Maciejewski JP Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3ABlood2011 11839323941

    Not in our library10.1182/blood-2010-10-311019

  33. 33.

    Pratcorona M Abbas S Sanders M Koenders J Kavelaars F Erpelinck-Verschueren C Zeilemaker A Lowenberg B Valk P Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic valueHaematologica2012 97388392doi:10.3324

    Not in our library10.3324/haematol.2011.051532

  34. 34.

    Ricci C Fermo E Corti S Molteni M Faricciotti A Cortelezzi A Lambertenghi Deliliers G Beran M Onida F RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variantClin Cancer Res2010 1622462256

    Not in our library10.1158/1078-0432.ccr-09-2112

  35. 35.

    Shen Y Zhu YM Fan X Shi JY Wang QR Yan XJ Gu ZH Wang YY Chen B Jiang CL Yan H Chen FF Chen HM Chen Z Jin J Chen SJ Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemiaBlood2011 11855935603

    Not in our library10.1182/blood-2011-03-343988

  36. 36.

    Stein BL Williams DM O'Keefe C Rogers O Ingersoll RG Spivak JL Verma A Maciejewski JP McDevitt MA Moliterno AR Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypesHaematologica2011 9614621469

    Not in our library10.3324/haematol.2011.045591

  37. 37.

    Thol F Friesen I Damm F Yun H Weissinger EM Krauter J Wagner K Chaturvedi A Sharma A Wichmann M Göhring G Schumann C Bug G Ottmann O Hofmann WK Schlegelberger B Heuser M Ganser A Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromesJ Clin Oncol2011 2924992506

    Not in our library10.1200/jco.2010.33.4938

  38. 38.

    Guglielmelli P Biamonte F Score J Hidalgo-Curtis C Cervantes F Maffioli M Fanelli T Ernst T Winkelman N Jones AV Zoi K Reiter A Duncombe A Villani L Bosi A Barosi G Cross NC Vannucchi AM EZH2 mutational status predicts poor survival in myelofibrosisBlood2011 11852275234

    Not in our library10.1182/blood-2011-06-363424

  39. 39.

    Damm F Kosmider O Gelsi-Boyer V Renneville A Carbuccia N Hidalgo-Curtis C Della-Valle V Couronné L Scourzic L Chesnais V Guerci-Bresler A Slama B Beyne-Rauzy O Schmidt-Tanguy A Stamatoullas-Bastard A Dreyfus F Prebet T Debotton S VEY N Morgan MA Cross NCP Preudhomme C Birnbaum D Bernard OA Fontenay M Mutations affecting m RNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromesBlood2012 in press

    Not in our library10.1182/blood-2011-12-400994

  40. 40.

    Metzeler KH Becker H Maharry K Radmacher MD Kohlschmidt J Mrózek K Nicolet D Whitman SP Wu YZ Schwind S Powell BL Carter TH Wetzler M Moore JO Kolitz JE Baer MR Carroll AJ Larson RA Caligiuri MA Marcucci G Bloomfield CD ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic categoryBlood2011 11869206929

    Not in our library10.1182/blood-2011-08-368225

All 53 references

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.